Immunoprecise Antibodies Ltd
XTSX:IPA
Immunoprecise Antibodies Ltd
Cash from Operating Activities
Immunoprecise Antibodies Ltd
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Immunoprecise Antibodies Ltd
XTSX:IPA
|
Cash from Operating Activities
-CA$600k
|
CAGR 3-Years
44%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Cash from Operating Activities
-$43.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Arch Biopartners Inc
XTSX:ARCH
|
Cash from Operating Activities
-CA$483.9k
|
CAGR 3-Years
39%
|
CAGR 5-Years
25%
|
CAGR 10-Years
-10%
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Cash from Operating Activities
-CA$2m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
Innovotech Inc
XTSX:IOT
|
Cash from Operating Activities
-CA$203k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
3%
|
CAGR 10-Years
9%
|
See Also
What is Immunoprecise Antibodies Ltd's Cash from Operating Activities?
Cash from Operating Activities
-600k
CAD
Based on the financial report for Apr 30, 2021, Immunoprecise Antibodies Ltd's Cash from Operating Activities amounts to -600k CAD.
What is Immunoprecise Antibodies Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
44%
Over the last year, the Cash from Operating Activities growth was 57%. The average annual Cash from Operating Activities growth rates for Immunoprecise Antibodies Ltd have been 44% over the past three years .